Help
RSS
API
Feed
Maltego
Contact
Domain > www.galvanypharma.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2025-12-15
52.212.226.238
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyDate: Mon, 15 Dec 2025 03:21:26 GMTServer: ApacheX-Content-Type-Options: nosniffX-Frame-Options: SAMEORIGINLocation: https://www.galvanypharma.com/Cache-Control: max-age0Expires: Mon, 15 Dec 2025 03:21:26 GMTContent-Length: 238Content-Type: text/html; charsetiso-8859-1 !DOCTYPE HTML PUBLIC -//IETF//DTD HTML 2.0//EN>html>head>title>301 Moved Permanently/title>/head>body>h1>Moved Permanently/h1>p>The document has moved a hrefhttps://www.galvanypharma.com/>here/a>./p>/body>/html>
Port 443
HTTP/1.1 200 OKDate: Mon, 15 Dec 2025 03:21:26 GMTServer: ApacheX-Content-Type-Options: nosniffX-Frame-Options: SAMEORIGINStrict-Transport-Security: max-age31536000; includeSubDomainsUpgrade: h2Connection: UpgradeLast-Modified: Wed, 21 May 2025 13:31:41 GMTAccept-Ranges: bytesContent-Length: 6147Cache-Control: max-age0Expires: Mon, 15 Dec 2025 03:21:26 GMTVary: Accept-EncodingContent-Type: text/html; charsetutf-8 ?xml version1.0 encodingUTF-8?>!DOCTYPE html>!--if lt IE 7> html langen-GB classno-js lt-ie9 lt-ie8 lt-ie7> !endif-->!--if IE 7> html langen-GB classno-js lt-ie9 lt-ie8> !endif-->!--if IE 8> html langen-GB classno-js lt-ie9> !endif-->!--if IE 9> html langen-GB classno-js ie9> !endif-->!--if gt IE 9>!--> html langen-GB xmlnshttp://www.w3.org/1999/xhtml classno-js> !--!endif-->head>meta charsetutf-8 />title>Delivering Patient Value | Galvany Pharma/title>meta http-equivX-UA-Compatible contentIEedge chrome1 />meta contentwidthdevice-width,initial-scale1 nameviewport />meta namegenerator contentBuilder />link relcanonical hrefhttps://www.galvanypharma.com/ />meta propertyog:title contentDelivering Patient Value />meta propertyog:type contentwebsite />meta propertyog:url contenthttps://www.galvanypharma.com/ />meta propertyog:site_name contentGalvany Pharma />meta nametwitter:card contentsummary />meta nametwitter:title contentDelivering Patient Value />meta namedc.date.issued contentWednesday 21 May 13:31 />meta namedcterms.alternative content175 />link relstylesheet typetext/css href/css/app.css?v1 />/head>body classfont-sans antialiased text-gray>div idapp classborder-t-3 border-purple>div classmax-w-5xl px-3 mx-auto>header classflex py-12 2md:flex-wrap justify-between>a href/>img src/images/logo_galvany.png altGalvany Pharma Logo />/a>top-nav>nav classflex ml-auto 2md:w-full>ul classflex gap-12 ml-auto 2md:ml-0 2md:flex-col 2md:w-full 2md:gap-3>li>a classitems-center font-bold 2md:w-full 2md:flex hover:opacity-90 2md:h-12 2md:bg-gray/10 2md:pl-3 href/>Home/a>/li>li>a classitems-center font-bold 2md:w-full 2md:flex hover:opacity-90 2md:h-12 2md:bg-gray/10 2md:pl-3 href/news>News/a>/li>li>a classitems-center font-bold 2md:w-full 2md:flex hover:opacity-90 2md:h-12 2md:bg-gray/10 2md:pl-3 href/products>Products/a>/li>li>a classitems-center font-bold 2md:w-full 2md:flex hover:opacity-90 2md:h-12 2md:bg-gray/10 2md:pl-3 href/management-team>Management Team/a>/li>li>a classitems-center font-bold 2md:w-full 2md:flex hover:opacity-90 2md:h-12 2md:bg-gray/10 2md:pl-3 href/responsibility>Responsibility/a>/li>li>a classitems-center font-bold 2md:w-full 2md:flex hover:opacity-90 2md:h-12 2md:bg-gray/10 2md:pl-3 href/contact>Contact/a>/li>/ul>/nav>/top-nav>/header>/div>main>div classmax-w-5xl px-3 mx-auto lg:px-0>div classmin-h-180px bg-gradient-to-t from-purple-200 to-purple-100 flex items-center relative>h1 classtext-3xl font-bold text-white ml-90px 2md:ml-3>Delivering Patient Value/h1>img src/images/logo-swoosh.png altlogo classabsolute bottom-0 left-0 right-0 />/div>/div>div classmax-w-5xl px-3 mx-auto>div classflex justify-between py-12 2md:flex-col 2md:gap-y-12>div classw-3/5 2md:w-full>div classprose >h2 classbeta>About Us/h2>Galvany Pharma is a UK-based pharmaceutical company specialising in the development and commercialisation of niche pharmaceuticals. The current Galvany portfolio consists of high quality products with targeted patient value in a number of diverse therapeutic areas. Galvany’s products meet unmet clinical medical need and strive to give patient access to alternative affordable medicines.span classrtebr>!--br-->/span>Galvany benefits from several strategic partnerships with leading manufacturers of medicines in Europe and across the world.span classrtebr>!--br-->/span>Galvany have a comprehensive commercial platform comprising a direct presence in the UK and several commercial partnerships enabling a Global reach.span classrtebr>!--br-->/span>The Galvany leadership team is built on a broad base of experience and high proven performance. Through our people we endeavour to exceed expectations of integrity, customer focus and operational excellence.span classrtebr>!--br-->/span>span classrtebr>!--br-->/span>span styletext-align: left; float: none;>b-button href/management-team>View Management team/b-button>/span>span classrtebr>!--br-->/span>/div>/div>div classw-30% 2md:w-full>h1 classuppercase text-purple font-bold mb-4>News/h1>div classpx-4 pt-4 pb-2 mb-5 bg-gray-100/10>time datetime2025-06>June 2025/time>h3 classfont-bold mb-4>Galvany launches Roxadin (Testosterone undecanoate)/h3>div classprose ellipsis>Galvany launches Roxadin (Testosterone undecanoate) 1000mg/4ml, solution for injection. This proposition provides a cost effective alternative for both prescribers and the pharmacy community.span classrtebr>!--br-->/span>/div>/div>div classpx-4 pt-4 pb-2 mb-5 bg-gray-100/10>time datetime2025-05>May 2025/time>h3 classfont-bold mb-4>Galvany launches Haloperidol/h3>div classprose ellipsis>Galvany launches Haloperidol 5mg/ml injection in a pack of 5; which is a cost effective alternative for both retail and hospital customers.span classrtebr>!--br-->/span>/div>/div>div classpx-4 pt-4 pb-2 mb-5 bg-gray-100/10>time datetime2024-10>October 2024/time>h3 classfont-bold mb-4>CPhI Milan 7th to 10th October 2024/h3>div classprose ellipsis>Galvany Pharma will attend CPhI Milan to meet with existing and potential new partners to further our development pipeline. Please contact us to arrange any meetings to discuss co-developments, contract development and licensing deals.span classrtebr>!--br-->/span>/div>/div>b-button href/news classw-full>Read More/b-button>/div>/div>/div>/main>div class py-6 bg-gray-100/10 mt-36 md:text-sm>div classflex items-center justify-between h-full px-3 mx-auto md:flex-col-reverse md:gap-4 max-w-10xl md:text-center>div>Copyright © 2025 Galvany Pharma/div>/div>/div>/div> script typetext/javascript src/js/app.js?v2> /script> /body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]